German researchers were stunned to discover that whole-body staging of patients with recently diagnosed malignancies using either MRI or PET/CT could miss a substantial number of metastatic lesions. They released their data at the 2007 RSNA meeting.
German researchers were stunned to discover that whole-body staging of patients with recently diagnosed malignancies using either MRI or PET/CT could miss a substantial number of metastatic lesions. They released their data at the 2007 RSNA meeting.
Dr. Florian Vogt and colleagues at the University Hospital of Essen enrolled 60 consecutive patients who underwent whole-body 1.5T MRI and whole-body FDG-PET/CT for staging of regional and distant melanoma metastases after primary tumor resection. Fifty-six patients completed the mean follow-up of 748 days. The researchers found that a significant number of patients initially staged as negative eventually proved to have undetected metastatic disease.
Another research group from Essen led by Dr. Gerald Antoch also evaluated the accuracy of whole-body FDG-PET/CT and whole-body MRI for staging and detection of bone metastases in 55 patients with melanoma and 54 with non-small cell lung cancer. The investigators found that, despite their accuracy for detection and staging, both tests yielded a significant rate of false negatives.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
Study: PET/MRI May Prevent Up to 83 Percent of Unnecessary Biopsies in Men with PI-RADS 3 Lesions
March 15th 2024For men with PI-RADS 3 lesions, PRIMARY scores of 4-5 with PET/MRI had a sensitivity rate of 87.5 percent for clinically significant prostate cancer, according to newly published research.